Please follow all preventive measures issued by official health authorities in the country with regard to Coronavirus (COVID-19). For any medical support or inquiry contact Estijaba service hotline at 8001717.
Concerned about Coronavirus (COVID-19)? Get your symptoms checked here! Free
Concerned about corona-virus-logo ?
Get a Free Risk Analysis
  Healthigo

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

By Mike Plum, GP


0 Comments,
  Likes

Mike Plum
GP


May 08, 2023

Scientists have worked at a record speed to develop COVID-19 vaccines and therapeutics to contain the pandemic. To date, all the vaccines and therapeutics (e.g., monoclonal antibodies) that received emergency use authorization from the global regulatory bodies have been designed against the spike protein of the original SARS-CoV-2 strain. However, the efficacy of the COVID-19 vaccines and therapeutics has been threatened due to mutations in the spike protein in the newly emerged SARS-CoV-2 strains. 

Mutations have increased the affinity of the spike protein for angiotensin-converting enzyme 2 (ACE2), which has brought about an increase in the infection rate. Additionally, some SARS-CoV-2 variants, such as the Delta strain, can evade the immune protection induced via natural infection and immunization targets. Hence, developing a new treatment that would remain effective against SARS-CoV-2 variants is urgently required. Generally, the spike protein of SARS-CoV-2 binds to ACE2 and, eventually, the virus enters the cell. After the virus enters the host cell, it captures its protein synthesis machinery and initiates viral replication.

Note : Please login to submit comment

All Comments

NO COMMENTS YET





scroll-arrow-to-up